VivoSeq
Immunology

Acute Graft Vs. Host Disease

32

Pipeline Programs↗

1

Active Trials↗

18

Companies Involved↗

Acute Graft Vs. Host Disease is a moderately active landscape with 32 programs across 18 companies. The most active players are Johnson & Johnson, AstraZeneca, GSK. 16 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

0/100

Mech. Concentration

14/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 1GSK logo

GSK

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

ApprovedJazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

69%

Small molecule

22 of 32 classified programs — the dominant modality here.

31%ALL OTHERSMonoclonal antibody722%Protein / enzyme26%Peptide13%

Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 100% of 33 pipeline programs.

Analysis

Trial Status

5

clinical trials

Completed4 · 80%
Recruiting1 · 20%

Clinical Trials

Trial Activity

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Completed·Novartis logoNovartis·Phase 3·NCT02913261·310 enrolled
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant
Completed·Sanofi logoSanofi·N/A·NCT00088543·60 enrolled
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
Recruiting·Novartis logoNovartis·Phase 4·NCT06462469·36 enrolled
A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease
Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT01700036·40 enrolled
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
Completed·Novartis logoNovartis·Phase 1/2·NCT03491215·45 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)